AU8016094A - Method of contraception - Google Patents

Method of contraception

Info

Publication number
AU8016094A
AU8016094A AU80160/94A AU8016094A AU8016094A AU 8016094 A AU8016094 A AU 8016094A AU 80160/94 A AU80160/94 A AU 80160/94A AU 8016094 A AU8016094 A AU 8016094A AU 8016094 A AU8016094 A AU 8016094A
Authority
AU
Australia
Prior art keywords
contraception
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU80160/94A
Inventor
Mary Lake Polan
Carlos Simon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of AU8016094A publication Critical patent/AU8016094A/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/689—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to pregnancy or the gonads
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/545—IL-1
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/36—Gynecology or obstetrics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/36—Gynecology or obstetrics
    • G01N2800/368—Pregnancy complicated by disease or abnormalities of pregnancy, e.g. preeclampsia, preterm labour

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU80160/94A 1993-10-12 1994-10-12 Method of contraception Abandoned AU8016094A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US136077 1980-03-28
US13607793A 1993-10-12 1993-10-12
PCT/US1994/011588 WO1995010298A1 (en) 1993-10-12 1994-10-12 Method of contraception

Publications (1)

Publication Number Publication Date
AU8016094A true AU8016094A (en) 1995-05-04

Family

ID=22471179

Family Applications (1)

Application Number Title Priority Date Filing Date
AU80160/94A Abandoned AU8016094A (en) 1993-10-12 1994-10-12 Method of contraception

Country Status (2)

Country Link
AU (1) AU8016094A (en)
WO (1) WO1995010298A1 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6858409B1 (en) 1988-05-27 2005-02-22 Amgen Inc. Nucleic acids encoding interleukin-1 inhibitors and processes for preparing interleukin-1 inhibitors
US6159460A (en) * 1988-05-27 2000-12-12 Amgen Inc. Method for treating interleukin-1 mediated diseases
US5075222A (en) 1988-05-27 1991-12-24 Synergen, Inc. Interleukin-1 inhibitors
ES2334726T3 (en) * 1996-02-09 2010-03-15 Amgen Inc. COMPOSITION THAT INCLUDES IL-1RA AS AN INHIBITOR OF INTERLEUCINE 1 AND HIALURONANE AS A CONTROLLED LIBERATION POLYMER.
AU748575B2 (en) * 1996-02-09 2002-06-06 Swedish Orphan Biovitrum Ab (Publ) Composition comprising interleukin-1 inhibitor and controlled release polymer
US6294170B1 (en) 1997-08-08 2001-09-25 Amgen Inc. Composition and method for treating inflammatory diseases
EP1141299A2 (en) 1998-12-23 2001-10-10 Genentech, Inc. Il-1 related polypeptides
EP1357934A1 (en) * 2001-02-06 2003-11-05 MERCK PATENT GmbH Modified interleukin-1 receptor antagonist (il-1ra) with reduced immunogenicity
GB0708376D0 (en) * 2007-05-01 2007-06-06 Alligator Bioscience Ab Novel polypeptides and uses thereof
ES2701405T3 (en) 2010-07-29 2019-02-22 Eleven Biotherapeutics Inc Agonists and antagonists of the type I receptor of chimeric IL-1
CN107693781B (en) 2013-03-13 2021-11-09 巴扎德制药公司 Chimeric cytokine formulations for ocular delivery
AU2016235298B2 (en) 2015-03-23 2021-03-11 Evestra, Inc. Novel cytotoxic agents that preferentially target leukemia inhibitory factor (LIF) for the treatment of malignancies and as new contraceptive agents

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4961436A (en) * 1987-07-17 1990-10-09 Brigham And Women's Hospital Contraceptive cervical cap
US5116619A (en) * 1988-08-30 1992-05-26 Lee Roy Morgan Vaginal progesterone tablet

Also Published As

Publication number Publication date
WO1995010298A1 (en) 1995-04-20

Similar Documents

Publication Publication Date Title
AU4013193A (en) Method of maintaining relationships between elements
AU7557594A (en) Method of fertilizer application
AU1322195A (en) Method of assay
AU7968694A (en) Bags and method of making bags
AU7700896A (en) Method of orienting cans
AU4868493A (en) Method of combining polymers
AU8016094A (en) Method of contraception
AU6752294A (en) Preparation process of acrylamide
PL313740A1 (en) Method of
AU3385693A (en) Determination method
AU6723294A (en) Use of simmondsine
AU6368394A (en) Polymer-polypeptide composition and method
AU3342093A (en) Lens and method of making same
EP0821576A4 (en) Method of contraception
AU1197495A (en) Method for abandonment of subseawells
AU3423693A (en) Methods of terminating pregnancy
AU7590794A (en) Method of sealing
AU1287095A (en) Package and method of making said package
AU1674295A (en) Preparation of doped polycarbynes
AU6905994A (en) Method of mining
AU7131094A (en) Method of laminate manufacture
AU3847693A (en) One-pot process
AU8099694A (en) Method of preventing disasters
AU7338294A (en) Method for endomodification of proteins
RU2003311C1 (en) Method of blepharorrhaphy